
Julia Beaver
@drjuliabeaver
oncologist, mother, wife, squash enthusiast.
All opinions my own. #clinicaltrials #precisiononcology #drugdevelopment
ID: 1204913038580686848
11-12-2019 23:57:22
207 Tweet
786 Followers
229 Following

Just published: FDA Approval Summary: Pralsetinib for the treatment of #lung and #thyroid cancers with RET gene mutations or fusions. First author Janice Kim @jankim1222, last author Harpreet Singh Harpreet Singh, MD via Clinical Cancer Research #lcsm #thyroidcancer clincancerres.aacrjournals.org/content/early/ā¦




New publication via Clinical Cancer Research : FDA Approval Summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. First author: Dr. Leigh Marcus; last author, Dr. Steven Lemery. Dr Lola Fashoyin-Aje Julia Beaver Rick Pazdur #TMB clincancerres.aacrjournals.org/content/early/ā¦

Final guidance on inclusion of premenopausal women in breast cancer clinical trials is published - fantastic collaborating with so many FDA Oncology and U.S. FDA colleagues on this important issue! Julia Beaver Laleh Amiri-Kordestani, MD #bcsm


To our new #Strongcope interns: Welcome to the The Osler Medical Residency family!! You all are AMAZING. Canāt wait to see you grow into the physician leaders we all know you will become #OslerPride Alex Horne ⦠Also, that selfie⦠#nailedit.


The Division of Oncology 1, FDA Office of Oncologic Diseases, hosted a retreat today at Cabin John Park, Bethesda, MD. It was a beautiful day and fantastic to see everyone in person. Rick Pazdur made it official with the obligatory selfie!



The Wild West of Checkpoint Inhibitor Development - Perspective by OCE's Julia Beaver and Rick Pazdur via NEJM. #cancerdrugdevelopment #FDA #ProjectOrbis nejm.org/doi/full/10.10ā¦

Very proud of this effort in collaboration with several colleagues from FDA Oncology (see list in RT below) reviewing important publications, considerations, and regulatory actions with respect to external control data in oncology: annalsofoncology.org/article/S0923-ā¦



Our FDA Oncology approval summary for belzutifan, a first-in-class HIF inhibitor which is the first drug approved for early treatment of von Hippel-Lindau disease-associated tumors Jaleh Fallah Gautam Mehta, MD Laleh Amiri-Kordestani, MD Julia Beaver pubmed.ncbi.nlm.nih.gov/35727604/



Critical Friends of Cancer Research collaborative effort across #Academia #pharma and FDA Oncology on #ctDNA dynamics for response monitoring during #immunotherapy just published in JCO Precision Oncology. Read here: trib.al/e6Fk2Na #CTMoniTR #WhatFriendsDoes #ctDNAFriends #LCSM Johns Hopkins Kimmel Cancer Center


#FDAOncology perspective: The On- and Off-Ramps of Oncology Accelerated Approval - via NEJM by Dr Lola Fashoyin-Aje Gautam Mehta, MD Julia Beaver Rick Pazdur nejm.org/doi/full/10.10ā¦

We are super excited to welcome the Class of 2026 to our program. They are all outstanding individuals who will do really well here Johns Hopkins Kimmel Cancer Center. Congratulations! #1Fellowship1Family

